Stock screener

NTLA

Conviction 72HealthcareScan · Fri, Jun 26, 2026
NTLA$16.65+3.87%
ResistanceSupportVol 14
63 bars
Vol MA14 7.37M
Mar 27Apr 15May 4May 20Jun 9Jun 26
WSB mentions · 24h changelatest +100.00%· 2 mentions
Mar 27Apr 15May 4May 20Jun 9Jun 26
Intellia Therapeutics, Inc.IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESwww.intelliatx.com
Price16.65
Change+3.87%
Gap-1.22%
Rel volume1.30×
Avg volume6.82M
Avg $ vol97.96M
SMA 2014.24
SMA 5013.92
SMA 20013.57
Price vs 50+19.65%
Price vs 200+22.72%
MA stackbullish
50/200 cross
Supertrendup · 12.81
RSI (14)65
MACD hist0.30
MACD crossbull · 8d
Stoch %K / %D94 / 85
ADX (14)26
+DI / −DI32 / 12
RSI divergence
MACD divergence
ATR %+7.06%
ADR %8.40%
52w high27.98
52w low8.04
From 52w high-40.49%
Above 52w low+107.09%
New 52w highNo
SqueezeOff
Bollinger width37.60%
%B0.95
Donchian pos94.16%
Donchian high16.95
Donchian low11.81
AVWAP (52w high)13.00
vs AVWAP high+28.09%
AVWAP (52w low)12.85
vs AVWAP low+29.62%
OBV trendUp
Chaikin MF (20)0.07
Today vs 20d1.30×
Avg vol (14d)7.37M
Avg vol (20d)6.82M
Avg $ vol (20d)97.96M
Market cap
RS 3m (vs SPY)+9.09%
RS 6m (vs SPY)+58.03%
RS line new highNo
Trend template5/8
Technical rank91.2
1 week+6.25%
1 month+23.88%
3 months+25.76%
6 months+76.75%
1 year+74.16%
YTD+80.78%
P/E-5.43
P/B3.61
P/S33.09
P/FCF-5.66
EPS-3.81
Div yield
ROE-66.46%
ROA-54.39%
Debt/Eq
Current6.10
EV/EBITDA-4.88
Gross margin
Net margin-609.85%
Rev growth16.92%
EPS growth20.49%
Price target21.06
Target upside31.42%
Analyst ratingBuy
Institutional90.10%
Ent. value2.1B
Revenue15.05M
Net income-96.23M
Gross profit
Free cash flow-395.87M
IndustryIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
ExchangeNasdaq
Shares out139.72M
Employees377
ListedFri, May 6, 2016
Free float
Float %
Short interest
Days to cover
Short volume
Squeeze score
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeB
Conviction72 / 100
Pattern quality
Tech rank91.2 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance16.14
Support11.80
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in NTLA

All disclosures →
No recent disclosed trades by Congress in NTLA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in NTLA · 10 buys

InsiderSideShares
Cohen Fred E
Director · Common Stock · 2026-06-09
Grant9.2K
Verwiel Frank
Director · Common Stock · 2026-06-09
Grant9.2K
Bhanji Muna
Director · Stock Option (right to buy) · 2026-06-09
Grant13.3K
Keresty Georgia
Director · Common Stock · 2026-06-09
Grant9.2K
Keresty Georgia
Director · Stock Option (right to buy) · 2026-06-09
Grant13.3K
GOODMAN JESSE
Director · Common Stock · 2026-06-09
Grant9.2K
GOODMAN JESSE
Director · Stock Option (right to buy) · 2026-06-09
Grant13.3K
CHASE WILLIAM J
Director · Common Stock · 2026-06-09
Grant9.2K
Verwiel Frank
Director · Stock Option (right to buy) · 2026-06-09
Grant13.3K
Goff Brian
Director · Common Stock · 2026-06-09
Grant9.2K

SEC filings

EDGAR filings in NTLA · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.